Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53BP1 | Q12888 | 4/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23366317 | 0.83 | TP53BP1 (0.53) | TP53BP1DGAT1ALDH1A1NR1H4LMNA | |
| SCHEMBL24518132 | 0.80 | TP53BP1 (0.38) | TP53BP1DGAT1ALDH1A1LMNAKMT2A | |
| SCHEMBL24555199 | 0.78 | TP53BP1 (0.47) | TP53BP1DGAT1ALDH1A1NR1H4LMNA | |
| SCHEMBL22545191 | 0.77 | TP53BP1 (0.52) | TP53BP1DGAT1ALDH1A1LMNAKMT2A | |
| SCHEMBL21308043 | 0.74 | ALDH1A1 (0.45) | ALDH1A1NR1H4KMT2ASMN1; SMN2GAA | |
| SCHEMBL16024506 | 0.73 | SPHK2 (0.44) | ALDH1A1NR1H4LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL21575547 | 0.73 | GAA (0.36) | DGAT1ALDH1A1NR1H4LMNAKMT2A | |
| SCHEMBL23957821 | 0.72 | NR1H4 (0.41) | ALDH1A1NR1H4LMNAKMT2AGAA | |
| SCHEMBL21307971 | 0.72 | KMT2A (0.42) | ALDH1A1NR1H4KMT2ASMN1; SMN2GAA | |
| SCHEMBL22327386 | 0.72 | NR1H4 (0.41) | ALDH1A1NR1H4KMT2ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008359-B2 | Labelled nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2021-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008359-B2 | Labelled nucleotides | NUDT1, DUT, NT5C2 | TP53BP1 3200/4885DGAT1 3028/4885ALDH1A1 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.